
Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Drug Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.
Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 15, 3, 35 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 11 and 3 molecules, respectively.
Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.
Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 15, 3, 35 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 11 and 3 molecules, respectively.
Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
Adjuvance Technologies Inc
Aelis Farma SAS
Aether Therapeutics Inc
Allaysis LLC
Amygdala Neurosciences Inc
Ananda Scientific Inc
Aphios Corp
Assertio Holdings Inc
Astraea Therapeutics LLC
Better Life Pharmaceuticals Inc
BioCorRx Inc
Camino Pharma LLC
Cerevel Therapeutics Holdings Inc
Charleston Laboratories Inc
Chiesi Farmaceutici SpA
Chiromics LLC
Clear Scientific LLC
Consegna Pharma Inc
Curemark LLC
D&A Pharma SAS
Daya Drug Discoveries Inc
DD Therapeutics LLC
Delix Therapeutics Inc
Denovo Biopharma LLC
Elysium Therapeutics Inc
Embera NeuroTherapeutics Inc
EncepHeal Therapeutics Inc
Ensysce Biosciences Inc
Entheon Biomedical Corp
EryDel SpA
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Hua Medicine Shanghai Ltd
IMV Inc
InterveXion Therapeutics LLC
Intra-Cellular Therapies Inc
Jazz Pharmaceuticals Plc
Kdac Therapeutics Inc
KemPharm Inc
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
MAKScientific LLC
MElkin Pharmaceuticals
Mind Medicine MindMed Inc
Mydecine Innovations Group Inc
Myosin Therapeutics Inc
Naprogenix Inc
NFL Biosciences SAS
Novartis AG
Omeros Corp
Ovid Therapeutics Inc
P2D Inc
PAION AG
Proniras Corp
Protagenic Therapeutics Inc
Qingdao Primedicine Pharmaceutical Technology Co Ltd
Relmada Therapeutics Inc
Revive Therapeutics Ltd
Saniona AB
Sen-Jam Pharmaceutical LLC
Tonix Pharmaceuticals Holding Corp
Trevena Inc
Tris Pharma Inc
Vallon Pharmaceuticals Inc
Vivozon Inc
Zelira Therapeutics Ltd
Companies Mentioned
Adjuvance Technologies Inc
Aelis Farma SAS
Aether Therapeutics Inc
Allaysis LLC
Amygdala Neurosciences Inc
Ananda Scientific Inc
Aphios Corp
Assertio Holdings Inc
Astraea Therapeutics LLC
Better Life Pharmaceuticals Inc
BioCorRx Inc
Camino Pharma LLC
Cerevel Therapeutics Holdings Inc
Charleston Laboratories Inc
Chiesi Farmaceutici SpA
Chiromics LLC
Clear Scientific LLC
Consegna Pharma Inc
Curemark LLC
D&A Pharma SAS
Daya Drug Discoveries Inc
DD Therapeutics LLC
Delix Therapeutics Inc
Denovo Biopharma LLC
Elysium Therapeutics Inc
Embera NeuroTherapeutics Inc
EncepHeal Therapeutics Inc
Ensysce Biosciences Inc
Entheon Biomedical Corp
EryDel SpA
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Hua Medicine Shanghai Ltd
IMV Inc
InterveXion Therapeutics LLC
Intra-Cellular Therapies Inc
Jazz Pharmaceuticals Plc
Kdac Therapeutics Inc
KemPharm Inc
Kinoxis Therapeutics Pty Ltd
Kyorin Pharmaceutical Co Ltd
MAKScientific LLC
MElkin Pharmaceuticals
Mind Medicine MindMed Inc
Mydecine Innovations Group Inc
Myosin Therapeutics Inc
Naprogenix Inc
NFL Biosciences SAS
Novartis AG
Omeros Corp
Ovid Therapeutics Inc
P2D Inc
PAION AG
Proniras Corp
Protagenic Therapeutics Inc
Qingdao Primedicine Pharmaceutical Technology Co Ltd
Relmada Therapeutics Inc
Revive Therapeutics Ltd
Saniona AB
Sen-Jam Pharmaceutical LLC
Tonix Pharmaceuticals Holding Corp
Trevena Inc
Tris Pharma Inc
Vallon Pharmaceuticals Inc
Vivozon Inc
Zelira Therapeutics Ltd
Table of Contents
192 Pages
- Introduction
- Global Markets Direct Report Coverage
- Drug Addiction - Overview
- Drug Addiction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Drug Addiction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Addiction - Companies Involved in Therapeutics Development
- Adjuvance Technologies Inc
- Aelis Farma SAS
- Aether Therapeutics Inc
- Allaysis LLC
- Amygdala Neurosciences Inc
- Ananda Scientific Inc
- Aphios Corp
- Assertio Holdings Inc
- Astraea Therapeutics LLC
- Better Life Pharmaceuticals Inc
- BioCorRx Inc
- Camino Pharma LLC
- Cerevel Therapeutics Holdings Inc
- Charleston Laboratories Inc
- Chiesi Farmaceutici SpA
- Chiromics LLC
- Clear Scientific LLC
- Consegna Pharma Inc
- Curemark LLC
- D&A Pharma SAS
- Daya Drug Discoveries Inc
- DD Therapeutics LLC
- Delix Therapeutics Inc
- Denovo Biopharma LLC
- Elysium Therapeutics Inc
- Embera NeuroTherapeutics Inc
- EncepHeal Therapeutics Inc
- Ensysce Biosciences Inc
- Entheon Biomedical Corp
- EryDel SpA
- F. Hoffmann-La Roche Ltd
- Foresee Pharmaceuticals Co Ltd
- Hua Medicine Shanghai Ltd
- IMV Inc
- InterveXion Therapeutics LLC
- Intra-Cellular Therapies Inc
- Jazz Pharmaceuticals Plc
- Kdac Therapeutics Inc
- KemPharm Inc
- Kinoxis Therapeutics Pty Ltd
- Kyorin Pharmaceutical Co Ltd
- MAKScientific LLC
- MElkin Pharmaceuticals
- Mind Medicine MindMed Inc
- Mydecine Innovations Group Inc
- Myosin Therapeutics Inc
- Naprogenix Inc
- NFL Biosciences SAS
- Novartis AG
- Omeros Corp
- Ovid Therapeutics Inc
- P2D Inc
- PAION AG
- Proniras Corp
- Protagenic Therapeutics Inc
- Qingdao Primedicine Pharmaceutical Technology Co Ltd
- Relmada Therapeutics Inc
- Revive Therapeutics Ltd
- Saniona AB
- Sen-Jam Pharmaceutical LLC
- Tonix Pharmaceuticals Holding Corp
- Trevena Inc
- Tris Pharma Inc
- Vallon Pharmaceuticals Inc
- Vivozon Inc
- Zelira Therapeutics Ltd
- Drug Addiction - Drug Profiles
- (hydrocodone bitartrate + naltrexone hydrochloride) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- (metyrapone + oxazepam) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- 6-BN - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AEF-0117 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AM-4113 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AM-4302 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ANS-6637 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AT-1001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AT-121 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AT-200 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AT-312 - Drug Profile
- Product Description
- Mechanism Of Action
- baclofen - Drug Profile
- Product Description
- Mechanism Of Action
- BETR-002 - Drug Profile
- Product Description
- Mechanism Of Action
- BICX-102 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
- Product Description
- Mechanism Of Action
- buprenorphine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cannabidiol - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cannabidiol - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cannabidiol - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CC-318 - Drug Profile
- Product Description
- Mechanism Of Action
- cebranopadol - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CHF-6563 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CM-1212 - Drug Profile
- Product Description
- Mechanism Of Action
- CS-1103 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CVL-354 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CVL-936 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CYD-179 - Drug Profile
- Product Description
- Mechanism Of Action
- DDD-024 - Drug Profile
- Product Description
- Mechanism Of Action
- dimethyltryptamine - Drug Profile
- Product Description
- Mechanism Of Action
- DLX-7 - Drug Profile
- Product Description
- Mechanism Of Action
- dronabinol - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Ery-CoCe - Drug Profile
- Product Description
- Mechanism Of Action
- esmethadone hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- FP-004 - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy for Methamphetamine Abuse - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse and Addiction - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- h-2E2 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ibudilast - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ITI-333 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IXTM-200 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IXTm-250 - Drug Profile
- Product Description
- Mechanism Of Action
- IXTV-100 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- JDTic - Drug Profile
- Product Description
- Mechanism Of Action
- JJC-8091 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KDAC-0001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KNX-100 - Drug Profile
- Product Description
- Mechanism Of Action
- KNX-300 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KNX-400 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KP-879 - Drug Profile
- Product Description
- Mechanism Of Action
- mavoglurant - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MC-100093 - Drug Profile
- Product Description
- Mechanism Of Action
- MP-1104 - Drug Profile
- Product Description
- Mechanism Of Action
- MT-110 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MYCO-004 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- naloxone - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NFL-201 - Drug Profile
- Product Description
- Mechanism Of Action
- NS-2359 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OMS-527 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OV-329 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- oxycodone hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- oxytocin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PMS-001 - Drug Profile
- Product Description
- Mechanism Of Action
- pomaglumetad methionil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- psilocybin - Drug Profile
- Product Description
- Mechanism Of Action
- PT-00114 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Enzyme for Cocaine Abuse - Drug Profile
- Product Description
- Mechanism Of Action
- remimazolam besylate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- RO-5256390 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SBP-0069330 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SJP-005 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Agonize MOR1 for Pain and Substance (Drug) Abuse - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Drug Abuse - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Substance Abuse and Drug Overdose - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Agonize CB1 and CB2 for CNS Diseases and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit DAT for Substance Abuse - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- sodium oxybate IR - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptide to Inhibit ELK1 for Central Nervous System Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile
- Product Description
- Mechanism Of Action
- tezampanel - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Titerquil-1055 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TNX-1300 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TRV-734 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Vaccine for Cocaine Addiction - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Vaccine for Drug Abuse - Drug Profile
- Product Description
- Mechanism Of Action
- Vaccine for Methamphetamine Addiction - Drug Profile
- Product Description
- Mechanism Of Action
- VVZN-3 - Drug Profile
- Product Description
- Mechanism Of Action
- XHeII-053 - Drug Profile
- Product Description
- Mechanism Of Action
- zolunicant hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Drug Addiction - Dormant Projects
- Drug Addiction - Discontinued Products
- Drug Addiction - Product Development Milestones
- Featured News & Press Releases
- Oct 04, 2021: InterveXion Therapeutics awarded federal grant to fund phase 2 study for methamphetamine use disorder
- Jun 30, 2021: Embera NeuroTherapeutics announces first subject dosed in phase 2a study of EMB-001 in smoking cessation
- Jun 24, 2021: Mydecine selects substance use disorder and smoking cessation for novel psychedelic molecule MYCO-004
- May 07, 2021: KemPharm announces serdexmethylphenidate (SDX) has been classified as a schedule IV controlled substance by the DEA
- Apr 19, 2021: InterveXion announces positive data in phase 2 study of IXT-m200 in participants with Methamphetamine use disorder
- Feb 22, 2021: Entheon Biomedical announces ethics approval for in vivo DMT study
- Jan 27, 2021: KemPharm receives FDA clearance to initiate KP879 clinical program for the treatment of stimulant use disorder
- Dec 22, 2020: KemPharm files IND for KP879 for the treatment of Stimulant Use Disorder
- Dec 09, 2020: Entheon Biomedical announces DMT drug supply agreement with Psygen Labs completion of initial DMT research drug batch and exercise of warrants
- Dec 01, 2020: Entheon Biomedical announces CRO agreement with CHDR for phase 1 clinical trial; Centre for Human Drug Research led DMT study to start in 2021
- Oct 05, 2020: InterveXion Therapeutics awarded federal grant to fund phase 2 study for Methamphetamine overdose
- Aug 31, 2020: Embera NeuroTherapeutics announces first subject dosed in phase 2 study of EMB-001 in cocaine use disorder
- Jan 30, 2020: Cerevel Therapeutics initiates phase 1 clinical trial of CVL-936, an investigational medicine in development to treat Substance Use Disorder
- Dec 04, 2019: Intra-Cellular Therapies to present data on ITI-333 at the 58th annual meeting of the American College of Neuropsychopharmacology
- Oct 07, 2019: BioCorRx announces capital restructuring and provides business update
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Drug Addiction, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Companies, 2022 (Contd..2)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Companies, 2022 (Contd..3)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Drug Addiction - Pipeline by Adjuvance Technologies Inc, 2022
- Drug Addiction - Pipeline by Aelis Farma SAS, 2022
- Drug Addiction - Pipeline by Aether Therapeutics Inc, 2022
- Drug Addiction - Pipeline by Allaysis LLC, 2022
- Drug Addiction - Pipeline by Amygdala Neurosciences Inc, 2022
- Drug Addiction - Pipeline by Ananda Scientific Inc, 2022
- Drug Addiction - Pipeline by Aphios Corp, 2022
- Drug Addiction - Pipeline by Assertio Holdings Inc, 2022
- Drug Addiction - Pipeline by Astraea Therapeutics LLC, 2022
- Drug Addiction - Pipeline by Better Life Pharmaceuticals Inc, 2022
- Drug Addiction - Pipeline by BioCorRx Inc, 2022
- Drug Addiction - Pipeline by Camino Pharma LLC, 2022
- Drug Addiction - Pipeline by Cerevel Therapeutics Holdings Inc, 2022
- Drug Addiction - Pipeline by Charleston Laboratories Inc, 2022
- Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, 2022
- Drug Addiction - Pipeline by Chiromics LLC, 2022
- Drug Addiction - Pipeline by Clear Scientific LLC, 2022
- Drug Addiction - Pipeline by Consegna Pharma Inc, 2022
- Drug Addiction - Pipeline by Curemark LLC, 2022
- Drug Addiction - Pipeline by D&A Pharma SAS, 2022
- Drug Addiction - Pipeline by Daya Drug Discoveries Inc, 2022
- Drug Addiction - Pipeline by DD Therapeutics LLC, 2022
- Drug Addiction - Pipeline by Delix Therapeutics Inc, 2022
- Drug Addiction - Pipeline by Denovo Biopharma LLC, 2022
- Drug Addiction - Pipeline by Elysium Therapeutics Inc, 2022
- Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, 2022
- Drug Addiction - Pipeline by EncepHeal Therapeutics Inc, 2022
- Drug Addiction - Pipeline by Ensysce Biosciences Inc, 2022
- Drug Addiction - Pipeline by Entheon Biomedical Corp, 2022
- Drug Addiction - Pipeline by EryDel SpA, 2022
- Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Drug Addiction - Pipeline by Foresee Pharmaceuticals Co Ltd, 2022
- Drug Addiction - Pipeline by Hua Medicine Shanghai Ltd, 2022
- Drug Addiction - Pipeline by IMV Inc, 2022
- Drug Addiction - Pipeline by InterveXion Therapeutics LLC, 2022
- Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, 2022
- Drug Addiction - Pipeline by Jazz Pharmaceuticals Plc, 2022
- Drug Addiction - Pipeline by Kdac Therapeutics Inc, 2022
- Drug Addiction - Pipeline by KemPharm Inc, 2022
- Drug Addiction - Pipeline by Kinoxis Therapeutics Pty Ltd, 2022
- Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
- Drug Addiction - Pipeline by MAKScientific LLC, 2022
- Drug Addiction - Pipeline by MElkin Pharmaceuticals, 2022
- Drug Addiction - Pipeline by Mind Medicine MindMed Inc, 2022
- Drug Addiction - Pipeline by Mydecine Innovations Group Inc, 2022
- Drug Addiction - Pipeline by Myosin Therapeutics Inc, 2022
- Drug Addiction - Pipeline by Naprogenix Inc, 2022
- Drug Addiction - Pipeline by NFL Biosciences SAS, 2022
- Drug Addiction - Pipeline by Novartis AG, 2022
- Drug Addiction - Pipeline by Omeros Corp, 2022
- Drug Addiction - Pipeline by Ovid Therapeutics Inc, 2022
- Drug Addiction - Pipeline by P2D Inc, 2022
- Drug Addiction - Pipeline by PAION AG, 2022
- Drug Addiction - Pipeline by Proniras Corp, 2022
- Drug Addiction - Pipeline by Protagenic Therapeutics Inc, 2022
- Drug Addiction - Pipeline by Qingdao Primedicine Pharmaceutical Technology Co Ltd, 2022
- Drug Addiction - Pipeline by Relmada Therapeutics Inc, 2022
- Drug Addiction - Pipeline by Revive Therapeutics Ltd, 2022
- Drug Addiction - Pipeline by Saniona AB, 2022
- Drug Addiction - Pipeline by Sen-Jam Pharmaceutical LLC, 2022
- Drug Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
- Drug Addiction - Pipeline by Trevena Inc, 2022
- Drug Addiction - Pipeline by Tris Pharma Inc, 2022
- Drug Addiction - Pipeline by Vallon Pharmaceuticals Inc, 2022
- Drug Addiction - Pipeline by Vivozon Inc, 2022
- Drug Addiction - Pipeline by Zelira Therapeutics Ltd, 2022
- Drug Addiction - Dormant Projects, 2022
- Drug Addiction - Dormant Projects, 2022 (Contd..1)
- Drug Addiction - Dormant Projects, 2022 (Contd..2)
- Drug Addiction - Dormant Projects, 2022 (Contd..3)
- Drug Addiction - Dormant Projects, 2022 (Contd..4)
- Drug Addiction - Discontinued Products, 2022
- List of Figures
- Number of Products under Development for Drug Addiction, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.